Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $55.5 million.

  • Foghorn Therapeutics' Cash & Equivalents rose 54.88% to $89.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.3 million, marking a year-over-year increase of 54.88%. This contributed to the annual value of $55.5 million for FY2024, which is 30.97% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Cash & Equivalents stood at $55.5 million for FY2024, which was down 30.97% from $80.3 million recorded in FY2023.
  • Foghorn Therapeutics' 5-year Cash & Equivalents high stood at $101.1 million for FY2021, and its period low was $52.2 million during FY2022.
  • In the last 3 years, Foghorn Therapeutics' Cash & Equivalents had a median value of $55.5 million in 2024 and averaged $62.7 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first slumped by 48.37% in 2022, then soared by 53.86% in 2023.
  • Foghorn Therapeutics' Cash & Equivalents (Yearly) stood at $92.8 million in 2020, then climbed by 8.99% to $101.1 million in 2021, then crashed by 48.37% to $52.2 million in 2022, then surged by 53.86% to $80.3 million in 2023, then tumbled by 30.97% to $55.5 million in 2024.